Peer-reviewed veterinary case report
Dogs with intestinal T-cell lymphoma showing both CD3 and CD20 markers
By Noland, Erica L. & Kiupel, Matti·Published in Veterinary Pathology·2018·Department of Pathobiology and Diagnostic Investigation, Veterinary Diagnostic Laboratory, Michigan State University, Lansing, MI, USA, United States·View original on Crossref →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Coexpression of CD3 and CD20 in Canine Enteropathy-Associated T-cell Lymphoma
- Species:
- dog
Plain-English summary
Three dogs diagnosed with enteropathy-associated T-cell lymphoma (EATL), a type of cancer affecting the intestines, showed unusual signs like weight loss, lack of appetite, diarrhea, and vomiting. These dogs, aged between 3 and 12 years, had a mix of T-cell and B-cell markers, which can affect treatment options. Their survival varied greatly, with some living just 20 days while others survived over a year and a half. Accurate diagnosis is crucial for determining the best treatment approach, but the impact of the B-cell marker on their condition is still uncertain.
People also search for: dog vomiting and weight loss · canine lymphoma treatment · EATL in dogs symptoms
Abstract
The majority of primary intestinal lymphomas in dogs are T-cell lymphomas, with enteropathy-associated T-cell lymphoma (EATL) large cell type (type 1) being the most common. While most T-cell lymphomas express the T-cell marker CD3, there is increasing evidence that some human and canine T-cell lymphomas coexpress the B-cell marker CD20. We describe 3 cases of CD3 + , CD20 + , Pax5 - EATL type 1 in dogs. All 3 cases had clonal rearrangement of T-cell receptor gamma. Initial clinical signs included weight loss, inappetence, diarrhea, and/or vomiting. The mean age was 9 years (range 3–12). Survival was highly variable ranging from 20 days to longer than 1.6 years. Considering the different chemotherapeutic response of T-cell versus B-cell lymphomas, accurate diagnosis of lymphomas coexpressing CD3 and CD20 as EATL type 1 based on histologic features and clonality results is important. Regardless, the clinical and/or prognostic significance of neoplastic T cells expressing CD20 is unclear.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on Crossref: https://doi.org/10.1177/0300985817747326